Trial Profile
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Cabazitaxel (Primary) ; Carboplatin (Primary) ; Ipilimumab (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DynaMO
- 07 Jun 2022 Results assessing overall survival, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 11 Feb 2022 Planned End Date changed from 1 May 2022 to 18 May 2023.
- 11 Feb 2022 Planned primary completion date changed from 1 May 2022 to 18 May 2023.